Form 4: IRADIMED CEO Sells Shares Under Pre-Arranged Plan

IRADIMED's CEO, President, and Chairman, Roger E. Susi, sold a total of 7,500 shares of common stock in mid-March 2026 under a pre-arranged trading plan.

Summary

• Roger E. Susi, the CEO, President, and Chairman of IRADIMED CORP (IRMD), reported sales of common stock.
• A total of 7,500 shares were sold across three transactions on March 16 and March 17, 2026.
• On March 16, 2026, 3,009 shares were sold at a weighted average price of $101.18 per share.
• Also on March 16, 2026, an additional 1,991 shares were sold at a weighted average price of $101.68 per share.
• On March 17, 2026, 2,500 shares were sold at a weighted average price of $102.43 per share.
• These sales were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Susi on November 5, 2025.
• Following these transactions, the Phillip Susi 2008 Dynasty Trust beneficially owns 2,240,000 shares indirectly.
• Mr. Susi also indirectly beneficially owns 162,950 shares via the Roger E. Susi Revocable Trust and 2,062,500 shares via the Matthew Susi 2008 Dynasty Trust, though he disclaims beneficial ownership of the latter except for his pecuniary interest.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative signal due to significant insider selling by the CEO, President, and Chairman, though the pre-arranged 10b5-1 plan provides context that these were planned transactions rather than opportunistic sales.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, which indicates the transactions were scheduled in advance and not based on immediate, non-public information.

Negatives

• The CEO, President, and Chairman sold a significant number of shares (7,500 shares), which can sometimes be interpreted by the market as a lack of confidence in the company's near-term prospects.
• The sales represent a reduction in the beneficial ownership of common stock held indirectly by a key executive.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• Roger E. Susi undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected for the multiple trades.

Industry Context

StockSavvy.ai notes that insider sales, even when conducted under a pre-arranged 10b5-1 plan, are closely monitored by investors. While 10b5-1 plans are designed to allow insiders to sell shares without being accused of trading on material non-public information, significant sales by a CEO and Chairman can still be interpreted as a signal about management's perception of the company's valuation or future prospects relative to personal financial planning.

Related Party Transactions

• The reporting person, Roger E. Susi, is the CEO, President, and Chairman of IRADIMED CORP, making these transactions related-party dealings.
• The sales were made from the Phillip Susi 2008 Dynasty Trust, an indirect beneficial ownership of the reporting person.

Stakeholder Impact

• Shareholders may interpret the sales by a key executive as a potential signal regarding the company's future performance or valuation, which could influence investor sentiment and stock price.
• The transactions could lead to increased scrutiny from investors regarding the company's fundamentals and management's long-term commitment.

Key Dates

Recommendation

The sale of shares by the CEO, President, and Chairman, Roger E. Susi, while executed under a pre-arranged 10b5-1 trading plan, represents a significant reduction in his direct beneficial ownership. While 10b5-1 plans aim to mitigate concerns about opportunistic insider trading, substantial sales by a key executive can still be interpreted by the market as a signal, potentially indicating that the executive believes the stock is fairly valued or that personal liquidity needs outweigh future growth prospects. Given the pre-planned nature, it's not an immediate 'sell' signal, but it warrants a 'hold' as investors assess the implications and monitor future company performance and insider activity.

Keywords

IRADIMED, IRMD, Roger Susi, Insider Trading, Stock Sale, Form 4, 10b5-1 Plan, CEO, Chairman, Executive Compensation